Results: Senores Pharmaceuticals Limited Beat Earnings Expectations And Analysts Now Have New Forecasts
Shareholders might have noticed that Senores Pharmaceuticals Limited (NSE:SENORES) filed its first-quarter result this time last week. The early response was not positive, with shares down 5.4% to ₹1,318 in the past week. It looks to have been a decent result overall - while revenue fell marginally short of analyst estimates at ₹1.8b, statutory earnings beat expectations by a notable 14%, coming in at ₹6.60 per share. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. So we collected the latest post-earnings statutory consensus estimates to see what could be in store for next year.
Following the latest results, Senores Pharmaceuticals' four analysts are now forecasting revenues of ₹9.14b in 2027. This would be a major 34% improvement in revenue compared to the last 12 months. Statutory earnings per share are predicted to shoot up 24% to ₹34.33. Before this earnings report, the analysts had been forecasting revenues of ₹8.86b and earnings per share (EPS) of ₹33.48 in 2027. So there seems to have been a moderate uplift in sentiment following the latest results, given the upgrades to both revenue and earnings per share forecasts for next year.
View our latest analysis for Senores Pharmaceuticals
It will come as no surprise to learn that the analysts have increased their price target for Senores Pharmaceuticals 38% to ₹1,620on the back of these upgrades. There's another way to think about price targets though, and that's to look at the range of price targets put forward by analysts, because a wide range of estimates could suggest a diverse view on possible outcomes for the business. There are some variant perceptions on Senores Pharmaceuticals, with the most bullish analyst valuing it at ₹1,795 and the most bearish at ₹1,500 per share. The narrow spread of estimates could suggest that the business' future is relatively easy to value, or thatthe analysts have a strong view on its prospects.
Of course, another way to look at these forecasts is to place them into context against the industry itself. The period to the end of 2027 brings more of the same, according to the analysts, with revenue forecast to display 48% growth on an annualised basis. That is in line with its 51% annual growth over the past year. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to see their revenues grow 12% per year. So it's pretty clear that Senores Pharmaceuticals is forecast to grow substantially faster than its industry.
The Bottom Line
The biggest takeaway for us is the consensus earnings per share upgrade, which suggests a clear improvement in sentiment around Senores Pharmaceuticals' earnings potential next year. Happily, they also upgraded their revenue estimates, and are forecasting them to grow faster than the wider industry. We note an upgrade to the price target, suggesting that the analysts believes the intrinsic value of the business is likely to improve over time.
With that said, the long-term trajectory of the company's earnings is a lot more important than next year. We have estimates - from multiple Senores Pharmaceuticals analysts - going out to 2029, and you can see them free on our platform here.
It might also be worth considering whether Senores Pharmaceuticals' debt load is appropriate, using our debt analysis tools on the Simply Wall St platform, here.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.